^
Association details:
| Biomarker: | DKK1 overexpression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | sirexatamab (DKN-01) (DKK1 protein inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Leap Therapeutics Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer
Published date:
09/24/2020
Excerpt:
...Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to DKN-01 for the treatment of patients with gastric and gastroesophageal junction (G/GEJ) adenocarcinoma whose tumors express high Dickkopf-1 protein (DKK1), following disease progression on or after prior fluoropyrimidine- and platinum- containing chemotherapy and if appropriate, human epidermal receptor growth factor (HER2)/neu-targeted therapy.
